NewAmsterdam Pharma Company N.V. (NAMS)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Descriptive
Exchange
Industry
Country
Active:none
| Company | Rating | |||||
|---|---|---|---|---|---|---|
| Loading data… | ||||||
Saved screens and full data - with a subscription
Subscribe to save filters and unlock all columns and ratings.
Subscribe - €24.90/mo